Alnylam Pharmaceuticals ALNY Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total revenues by Product | |||||
| AMVUTTRA | $2.31B+138% | $970.45M+74.0% | $557.84M+495% | $93.8M— | |
| GIVLAARI | $308.49M+20.6% | $255.87M+16.7% | $219.25M+26.6% | $173.14M+35.5% | |
| ONPATTRO | $172.79M-31.7% | $252.86M-28.7% | $354.55M-36.4% | $557.61M+17.5% | |
| OXLUMO | $191.44M+14.6% | $167.05M+52.1% | $109.84M+57.4% | $69.78M+17.1% | |
| Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements by Product | |||||
| Vutrisiran | $77.71M— | —— | —— | —— | |
| Zilebesrian | $21.13M— | —— | —— | —— | |
| Interest Expense by Product | |||||
| Vutrisiran | $81.74M— | —— | —— | —— | |
| Zilebesrian | $6.85M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Alnylam Pharmaceuticals break its business down?
- Alnylam Pharmaceuticals (ALNY) reports total revenues by product across 4 parts — AMVUTTRA, GIVLAARI, ONPATTRO and OXLUMO. Each is extracted from the segment footnotes and tracked over time.
- Where does Alnylam Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Alnylam Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
